Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
MENLO PARK, Calif., March 28, 2017 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it will present at the Needham & Company 16th Annual Healthcare Conference. Andrew Guggenhime, chief operating officer and chief financial officer of Dermira, is scheduled to present at 2:20 p.m. ET (11:20 a.m. PT) on Tuesday, April 4, 2017, in New York. A live audio webcast and replay of the presentation will be available on the Investors section of Dermira’s corporate website at www.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s product pipeline includes three Phase 3 product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), in development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); CIMZIA® (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; and olumacostat glasaretil (formerly DRM01), in development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, Calif. For more information, please visit www.dermira.com.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website and LinkedIn page in addition to following its SEC filings, press releases, public conference calls and webcasts.
Contacts: Media: Erica Jefferson Senior Director, Head of Corporate Communications 650-421-7216 [email protected] Investors: Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650-421-7200 [email protected] Robert H. Uhl Westwicke Partners Managing Director 858-356-5932 [email protected]
